Results 211 to 220 of about 13,757,225 (358)

Efficacy and safety of a selective partial agonist for nociception/orphanin‐FQ peptide (NOP) receptors in patients with insomnia disorder

British Journal of Clinical Pharmacology, EarlyView.
Aims Insomnia is a common sleep disorder, affecting up to 20% of the world population and adversely impacting productivity, health, and overall well‐being. Although pharmacologic options exist to treat insomnia, the health‐related quality of life for patients who are prescribed hypnotics is no higher than for those who are not, revealing a significant ...
Garth T. Whiteside, Ellie He, S. Shet Manjunath, Mingyan Zhou, Maha Ahmad, Stephen C. Harris   +5 more
wiley   +1 more source

On the future of therapeutic vaccination in chronic hepatitis B

Future Science OA, 2019
Julio Cesar Aguilar Rubido
doaj   +1 more source

Estimated prevalence of hepatitis B and C among immigrants in Canada. [PDF]

Can Commun Dis Rep
Campeau L, Elliott J, Williams A, Périnet S, Yang Q, Cox J, Feld JJ, Greenaway C, Popovic N.   +8 more
europepmc   +1 more source

Primary liver cell carcinoma in the presence or absence of hepatitis b antigen [PDF]

, 1976
Rosemarie Lucianin Fisher, Peter J. Scheuer, Sheila Sherlock   +2 more
openalex   +1 more source

Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV

British Journal of Clinical Pharmacology, EarlyView.
Aim Concomitant treatment of tuberculosis (TB) and human immunodeficiency virus (HIV) is complicated by drug‐drug interactions (DDI). This analysis aimed to characterize the DDI between ritonavir‐boosted atazanavir (ATV/r) and rifampicin in plasma and peripheral blood mononuclear cells (PBMC).
Allan Kengo, Juan Eduardo Resendiz‐Galvan, Letisha Najjemba, Henry Mugerwa, Amedeo De Nicolò, Antonio D'Avolio, Shakir Atoyebi, Lubbe Wiesner, Elin M. Svensson, Catriona Waitt, Paolo Denti   +10 more
wiley   +1 more source

Quantitative Change of Hepatitis B Surface Antigen Leading to Final Hepatitis B Surface Antigen Loss in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in China. [PDF]

Clin Transl Gastroenterol
Zhou T, Shu M, Luo F, Dong S, Teng J, Du Y, Qiu H, Cai W.   +7 more
europepmc   +1 more source

Hepatitis B in hemodialysis patients: Significance of HBeAg

, 1978
Denis J. Miller, Alan Williams, George L. Le Bouvier, John M. Dwyer, James Grant, Gerald Klatskin   +5 more
openalex   +1 more source

Adverse drug reactions, particularly liver disorders, drive interruptions in anti‐tuberculosis treatment: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims Adverse drug reactions (ADRs) are a key driver of missed doses of anti‐tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR‐driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses.
Eleanor G. Dixon, Evita Biraua, Edvards Brencsēns, Vitālijs Pašuks, Vija Riekstina, Anete Šperberga, Marisa D. Muckian, James W. Dear, Liga Kuksa, Derek J. Sloan, Helen R. Stagg   +10 more
wiley   +1 more source

Juvenile Dermatomyositis and Hepatitis B Viral Infection. [PDF]

Eur J Case Rep Intern Med
Younis AA, Ahmed Al-Harbi AA.
europepmc   +1 more source

HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant.

Gastroenterology, 2016
W. Mason, U. Gill, S. Litwin, Yan Zhou, S. Peri, O. Pop, M. Hong, S. Naik, A. Quaglia, A. Bertoletti, P. Kennedy   +10 more
semanticscholar   +1 more source